文献速递痛风与晶体性关节病

痛风患者双能CT测量的单钠尿酸盐晶体消退动力学的影响因素

Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout.
PubMed 文献 · RMD Open · 2023-01-01

纳入62例基线膝和足双能CT显示单钠尿酸盐晶体体积≥0.1 cm³且有至少一次随访双能CT的痛风患者,共104次随访扫描。血清尿酸盐水平与晶体体积百分比变化呈良好相关(r=0.66,p<0.0001)。12个月时达到<5.0 mg/dL目标者的晶体体积中位下降幅度大于达到≥5.0且<6.0 mg/dL者:-85%(95%CI:-94%至-72%)对-40%(-57%至-22%,p<0.05)。结论认为达到<5.0 mg/dL目标比达到<6.0 mg/dL目标提供更广泛和更快速的晶体溶解。

要点

  • 血清尿酸盐水平与双能CT测量的单钠尿酸盐晶体体积百分比变化呈良好相关(r=0.66,p<0.0001)。
  • 12个月时达到<5.0 mg/dL者晶体体积中位下降-85%,大于达到≥5.0且<6.0 mg/dL者的-40%(p<0.05)。
  • 多变量分析中仅时间、高血压和血清尿酸盐<5.0 mg/dL与晶体体积变化显著相关。

核心结论

  • 在双能CT测量单钠尿酸盐晶体沉积的痛风患者中,达到<5.0 mg/dL血清尿酸盐目标比达到<6.0 mg/dL目标提供更广泛和更快速的晶体溶解。

研究设计与样本

  • 纳入确诊痛风、基线膝和足双能CT扫描显示单钠尿酸盐晶体体积≥0.1 cm³且至少有一次随访双能CT的患者。
  • 共纳入62例患者(年龄67.3±12.8岁;53例(85%)为男性),累计104次随访双能CT扫描。
  • 采用Spearman相关系数分析基线与6、12、18和24个月时单钠尿酸盐晶体体积变化与血清尿酸盐水平的关联。
  • 采用线性混合模型评估单钠尿酸盐晶体沉积体积基线百分比变化与解释变量之间的关联。

主要发现

  • 总体而言,分别有48例(77%)和36例(58%)患者达到血清尿酸盐目标水平(<6.0和<5.0 mg/dL)。
  • 血清尿酸盐水平与单钠尿酸盐晶体体积百分比变化之间观察到良好相关(r=0.66;p<0.0001)。
  • 12个月时,达到<5.0 mg/dL血清尿酸盐目标者的单钠尿酸盐晶体体积中位下降幅度大于达到≥5.0且<6.0 mg/dL者:-85%(95%CI:-94%至-72%)对-40%(-57%至-22%;p<0.05)。
  • 多变量分析中,时间(以天计,多水平系数为-0.06,95%CI:-0.08至-0.03,p<0.001)、高血压(系数:41.87,95%CI:16.38至67.18,p<0.01)和血清尿酸盐水平<5.0 mg/dL(系数:-39.46,95%CI:-70.93至-8.34,p=0.02)是仅有的与单钠尿酸盐晶体体积变化显著相关的变量。

关键数值与推荐

  • 血清尿酸盐目标<6.0 mg/dL由48例(77%)患者达到,<5.0 mg/dL由36例(58%)患者达到。
  • 12个月时达到<5.0 mg/dL者单钠尿酸盐晶体体积中位下降-85%(95%CI:-94%至-72%),达到≥5.0且<6.0 mg/dL者中位下降-40%(-57%至-22%),组间p<0.05。
  • 多变量分析中时间系数-0.06(95%CI:-0.08至-0.03,p<0.001),高血压系数41.87(95%CI:16.38至67.18,p<0.01),血清尿酸盐<5.0 mg/dL系数-39.46(95%CI:-70.93至-8.34,p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine factors influencing the kinetics of monosodium urate (MSU) crystal dissolution measured with dual-energy computed tomography (DECT) during follow-up of patients with gout. METHODS: Patients with a diagnosis of gout with baseline knees and feet DECT scans exhibiting MSU crystal volumes ≥0.1 cm3 and at least one follow-up DECT were included. Spearman's correlation coefficient was used to search for association between change from baseline MSU crystal volume at 6, 12, 18 and 24 months and serum urate (SU) level. Associations between percentage change from the baseline volume of MSU crystal deposits and explanatory variables were assessed using linear mixed models. RESULTS: Sixty-two patients (age 67.3±12.8 years; 53 (85%) males) cumulating 104 follow-up DECT scans were included. Overall, SU target levels (<6.0 and <5.0 mg/dL) were achieved by 48 (77%) and 36 (58%) patients, respectively. There was a good correlation (r=0.66; p<0.0001) observed between SU level and percentage change in MSU crystal volume. The median decrease from baseline MSU crystal volume was greater in patients reaching the <5.0 mg/dL SU target than in those reaching ≥5.0 SU <6.0 mg/dL: -85% (95% CI: -94% to -72%) versus -40% (-57% to -22%; p<0.05) at 12 months. In multivariable analysis, time (in days) with a multilevel coefficient of -0.06 (95% CI: -0.08 to -0.03, p<0.001), hypertension (coefficient: 41.87, 95% CI: 16.38 to 67.18, p<0.01) and SU level <5.0 mg/dL (coefficient: -39.46, 95% CI: -70.93 to -8.34, p=0.02) were the only variables significantly associated with MSU crystal volume change. CONCLUSION: In patients with DECT-measured MSU crystal deposition, reaching the <5.0 mg/dL SU target provides more extensive and rapid crystal dissolution than reaching the <6.0 mg/dL SU target.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Laurent V, Jauffret C, Pacaud A, et al. Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout. RMD Open. 2023. PMID: 37940341. doi:10.1136/rmdopen-2023-003725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。